Sign In
Buy BGNE
$184.71
+0 (+0%)
At Close: Mar 28, 2025
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
11:19am, Thursday, 03'rd Apr 2025
BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
06:00am, Thursday, 03'rd Apr 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today a
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
06:00am, Monday, 31'st Mar 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
08:37am, Tuesday, 04'th Mar 2025
On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or m
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
02:00pm, Friday, 28'th Feb 2025
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Thursday, 27'th Feb 2025
While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
10:24am, Thursday, 27'th Feb 2025
BeiGene, Ltd. (NASDAQ:ONC ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
06:00am, Thursday, 27'th Feb 2025
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today an
BeiGene to Present at Upcoming Investor Conferences
06:01am, Tuesday, 25'th Feb 2025
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today an
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
04:26am, Friday, 21'st Feb 2025
BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
06:01am, Thursday, 13'th Feb 2025
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will rep
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
06:00am, Monday, 23'rd Dec 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announ
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
07:30pm, Thursday, 12'th Dec 2024
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today an
